How effective is gefitinib (Iressa) for treating lung cancer?

Iressa (gefitinib) Iressa (gefitinib) is beneficial for " treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies " See: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41.

Related Questions

How effective iressa (gefitinib) for lung cancer after chemo?

Only if .. Gefitinib will only work if there is a egfr mutation detected on the cancer. It will not be effective if there is no egfr mutation detected. Read more...
Not used. Really not used anymore since the company sponsored trial showed no benefit. Now tarceva (erlotinib) has essentially replaced iressa (gefitinib). If patients have a mutation in egfr (not kras), probably better than chemotherapy. There was a trial that did show a benefit after chemotherapy in patients with a mutation. Hope this helps. Read more...

Mum diagnosed with stage 4 lung cancer. Mass in upper right airway caused major blockage. Iressa (gefitinib) treatment opens up airway. Any chances of recovery?

Targeted therapy. Newer targeted therapy agents can be quite beneficial for some patients with lung cancer. This is especially true in female never smokers who may have selected mutations that can be easily targeted with these drugs. However, unfortunately stage IV lung cancer is not curable. Read more...
No cure but... ... It's likely you and your mother have gained several good months to share with one another. Until recently, we had nothing like iressa; these targeted therapies are remarkable. Read more...
It depends... ...On one's perception of "recovery" is. If the expectation from treatment is palliative or symptomatic relief, then she will recover. Breathing is an issue and so long as she breathes, that is a welcome progress. On the other hand, there is no "cure" for stage IV lung cancer. But, everyday she breathes well is a good day. Let us think positive especially when the negative is overwhelming. Read more...